Randomized trial cohort analysis reveals potential efficacy of low-dose LMTM monotherapy in mild Alzheimer's disease, suggesting four milligrams twice daily matches higher doses.
The results are consistent with earlier studies in supporting the hypothesis that LMTM might be effective as monotherapy and that 4 mg twice a day may serve as well as higher doses. A further suitably randomized trial is required to test this hypothesis.
No takes yet. Share an insight, caveat, or question.
Wilcock et al. (2017) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: